Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The promise of combining navitoclax and ruxolitinib in MF

Claire Harrison • 24 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Navitoclax Ruxolitinib
TRANSFORM-1 TRANSFORM-2

In this video, Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the promise of combining navitoclax with ruxolitinib for the treatment of myelofibrosis (MF), and important factors to consider when selecting patients for this combination. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

More from Claire Harrison

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
1:58
The value of novel JAK2 and CALR-targeted therapies in MPNs
Claire Harrison • 24 Apr 2023
1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals